11.12.2009 • News

Bristol-Myers Sells Asia Rights to Taisho

Bristol-Myers Squibb said it will sell Asia rights to over-the-counter drugs and its Indonesian unit to Japan's Taisho Pharmaceutical for $310 million, its seventh deal aimed at helping it focus on prescription drugs. Taisho, Japan's biggest maker of non-prescription drugs will make its first full-fledged entry into Asia's OTC drug market. The move by Taisho is the latest in a string of overseas acquisitions by Japanese drugmakers seeking to beef up their development pipelines and expand outside a mature home market and whose buying power has been helped by a strong yen. Bristol said it will sell the Asia rights to a batch of products, including painkillers Tempra and Counterpain, for $160 million and its 98 % stake in Bristol-Myers Squibb Indonesia for $150 million.

From Catalogue to Collaboration

Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.